Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for painful skin condition: experimental drug CIT-013 enters Mid-Stage trial

NCT ID NCT06993233

Symptom relief Sponsor: Citryll BV Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new drug called CIT-013 can reduce symptoms of hidradenitis suppurativa, a chronic skin condition causing painful lumps. About 96 adults with moderate to severe HS will receive either 50 mg, 100 mg, or a placebo every two weeks for 12 weeks. Researchers will check if the drug lowers disease activity and monitor for any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 96 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants with HS of more than 6 months duration, * 18 years of age at screening visit, * Hidradenitis suppurativa lesions present in ≥ 2 distinct anatomic areas, one of which is Hurley Stage II or III (according to Hurley classification system), * A total abscess and inflammatory nodule (AN) count of ≥ 5 at screening and Day 1 prior to enrollment/randomization, * Participant must have had an inadequate response to oral antibiotics OR exhibited recurrence after discontinuation to, OR demonstrated intolerance to, OR have a contraindication to oral antibiotics for treatment of their HS, * Total draining tunnel count less than 20 Exclusion Criteria: \- Participants for whom an approved therapy with demonstrated clinical benefit is indicated, available and expected to be tolerated, OR choose to proceed with standard of care treatment options over the IP (after being appropriately informed of the treatment options, risks, and benefits). Any current and/or recurrent clinically significant skin condition in the treatment area other than HS, * Prior treatment with a recombinant therapeutic protein during the 6 weeks before baseline * Prior treatment with any of the following medications before baseline: 1. Any other systemic therapy for HS (28 days before baseline) 2. Any IV anti-infective therapy (14 days before baseline) * History of malignancy with exception of non-melanoma skin cancer that has been excised and cured,

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa (HS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa (HS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    28 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CA-01

    RECRUITING

    Barrie, Canada

  • CA-02

    RECRUITING

    London, Canada

  • CA-03

    RECRUITING

    Winnipeg, Canada

  • CA-04

    RECRUITING

    Newmarket, Canada

  • CA-05

    RECRUITING

    Calgary, Canada

  • DE-01

    RECRUITING

    Bochum, Germany

  • DE-02

    RECRUITING

    Frankfurt, Germany

  • DE-03

    RECRUITING

    Oldenburg, Germany

  • DE-04

    RECRUITING

    Dresden, Germany

  • DE-06

    RECRUITING

    Bad Bentheim, Germany

  • DE-08

    RECRUITING

    Kiel, Germany

  • ES-01

    RECRUITING

    Valencia, Spain

  • ES-02

    NOT_YET_RECRUITING

    Santiago de Compostela, Spain

  • ES-03

    NOT_YET_RECRUITING

    Seville, Spain

  • ES-04

    NOT_YET_RECRUITING

    Madrid, Spain

  • ES-05

    NOT_YET_RECRUITING

    Barcelona, Spain

  • Erasmus UMC

    RECRUITING

    Rotterdam, Netherlands

  • GB-02

    RECRUITING

    Cardiff, United Kingdom

  • GB-04

    RECRUITING

    London, United Kingdom

  • GB-05

    RECRUITING

    Chester, United Kingdom

  • PL-01

    RECRUITING

    Rzeszów, Poland

  • PL-02

    NOT_YET_RECRUITING

    Lodz, Poland

  • PL-03

    RECRUITING

    Katowice, Poland

  • PL-05

    RECRUITING

    Wroclaw, Poland

  • PL-06

    RECRUITING

    Bialystok, Poland

  • PL-08

    RECRUITING

    Gdansk, Poland

  • PL-09

    RECRUITING

    Poznan, Poland

  • PL-10

    RECRUITING

    Lodz, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.